[The trial of intravenous L-DOPA in patients with Parkinson's disease].
D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D010919:Placebos; D004295:Dihydroxyphenylalanine
Test con L-DOPA per via endovenosa nei pazienti con morbo di Parkinson.